Gracell Biotechnologies Investor Relations Material
Latest events
Q3 2023
Gracell Biotechnologies
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Gracell Biotechnologies Inc
Access all reports
Gracell Biotechnologies Inc. (GRCL) is a clinical-stage biopharmaceutical company primarily focused on discovering and developing innovative cell therapies for cancer treatment. The company leverages its proprietary FasTCAR and TruUCAR technology platforms, along with its SMART CART™ technology module, to develop therapies designed to offer fast, deep, and durable responses for patients suffering from cancer and autoimmune diseases. Gracell Biotechnologies is headquartered in Suzhou, China, and its shares are listed on the Nasdaq.
Latest articles
)
Maziar Mike Doustdar: Novo Nordisk's New CEO
A portrait of the pharmaceutical giant's new CEO, who assumes the position at a critical time for the company in its competition with Eli Lilly.
12 Aug 2025
)
Novo Nordisk: Tipping the Scale of Innovation
Taking a look at the company behind Ozempic and Wegovy and diving into their history, business, and the challenges it now faces
8 Aug 2025
)
Global Doughmination: Breaking Down Domino's Pizza
Inside the rise of Domino's Pizza: how franchising, delivery control, and supply chain mastery built one of the world's most efficient food empires.
18 Jul 2025
Ticker symbol
GRCL
Country
🇺🇸 United States